Senior UK Regulator Gets 'Slightly Defensive' Over Relative EU/US Accelerated Pathway Approval Times
This article was originally published in SRA
Executive Summary
Comparing and contrasting drug approval times under the various accelerated access tools that are available in the EU and the US is not necessarily a useful exercise, a senior UK regulator has implied.